Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

Kite Pharma is flying high with the addition of a new member to its senior leadership team. Brian Heath has joined Gilead Sciences’ cell therapy subsidiary as a senior vice president and head of ...

The pharma company needs to ensure Kite generates major revenues over the long term, which will require it to expand its cell therapies beyond Yescarta’s first licensed use in diffuse large B ...

A California federal district court denied Gilead Sciences, Inc. and Kite Pharma, Inc.’s motion to dismiss unpaid overtime claims under the Fair Labor Standards Act by two cell therapy specialists ...

The former Kite Pharma executive has identified stiff person syndrome (SPS), a rare autoimmune neurological disorder launched into public attention by Céline Dion’s diagnosis, as the initial ...

In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid manufactured anti-CD19/CD20 CAR T-cell ...

U.S. Rep. April McClain Delaney visited Kite, a biopharmaceutical company that uses cell therapy to treat cancer, in Urbana on Thursday morning, one of several locations across her district she ...

Through its partnership in 2017 with California-based Kite Pharma, Fosun Pharma has been co-developing the CAR-T therapy in China. Its biopharmaceutical platform, Henlius is developing biosimilars ...

Sirion Biotech has announced it will be attending the ESGCT XXV Anniversary Congress, in collaboration with the German Society ...